TY - JOUR
T1 - Evidence that activation of nuclear factor-κB is essential for the cytotoxic effects of doxorubicin and its analogues
AU - Ashikawa, Kazuhiro
AU - Shishodia, Shishir
AU - Fokt, Izabel
AU - Priebe, Waldemar
AU - Aggarwal, Bharat B.
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2004/1/15
Y1 - 2004/1/15
N2 - Several reports within the last 5 years have suggested that nuclear factor (NF)-κB activation suppresses apoptosis through expression of anti-apoptotic genes. In the present report, we provide evidence from four independent lines that NF-κB activation is required for the cytotoxic effects of doxorubicin. We used doxorubicin and its structural analogues WP631 and WP744, to demonstrate that anthracyclines activate NF-κB, and this activation is essential for apoptosis in myeloid (KBM-5) and lymphoid (Jurkat) cells. All three anthracyclines had cytotoxic effects against KBM-5 cells; analogue WP744, was most potent, with an IC50 of 0.5μM, and doxorubicin was least active, with an IC50 of 2μM. We observed maximum NF-κB activation at 1μM with WP744 and at 50μM with doxorubicin and WP631, and this activation correlated with the IκBα degradation. Because the anthracycline analogue (WP744), most active as a cytotoxic agent, was also most active in inducing NF-κB activation and the latter preceded the cytotoxic effects, suggests that NF-κB activation may mediate cytotoxicity. Second, receptor-interacting protein-deficient cells, which did not respond to doxorubicin-induced NF-κB activation, were also protected from the cytotoxic effects of all the three anthracyclines. Third, suppression of NF-κB activation by pyrrolidine dithiocarbamate, also suppressed the cytotoxic effects of anthracyclines. Fourth, suppression of NF-κB activation by NEMO-binding domain peptide, also suppressed the cytotoxic effects of the drug. Overall our results clearly demonstrate that NF-κB activation and IκBα degradation are early events activated by doxorubicin and its analogues and that they play a critical pro-apoptotic role.
AB - Several reports within the last 5 years have suggested that nuclear factor (NF)-κB activation suppresses apoptosis through expression of anti-apoptotic genes. In the present report, we provide evidence from four independent lines that NF-κB activation is required for the cytotoxic effects of doxorubicin. We used doxorubicin and its structural analogues WP631 and WP744, to demonstrate that anthracyclines activate NF-κB, and this activation is essential for apoptosis in myeloid (KBM-5) and lymphoid (Jurkat) cells. All three anthracyclines had cytotoxic effects against KBM-5 cells; analogue WP744, was most potent, with an IC50 of 0.5μM, and doxorubicin was least active, with an IC50 of 2μM. We observed maximum NF-κB activation at 1μM with WP744 and at 50μM with doxorubicin and WP631, and this activation correlated with the IκBα degradation. Because the anthracycline analogue (WP744), most active as a cytotoxic agent, was also most active in inducing NF-κB activation and the latter preceded the cytotoxic effects, suggests that NF-κB activation may mediate cytotoxicity. Second, receptor-interacting protein-deficient cells, which did not respond to doxorubicin-induced NF-κB activation, were also protected from the cytotoxic effects of all the three anthracyclines. Third, suppression of NF-κB activation by pyrrolidine dithiocarbamate, also suppressed the cytotoxic effects of anthracyclines. Fourth, suppression of NF-κB activation by NEMO-binding domain peptide, also suppressed the cytotoxic effects of the drug. Overall our results clearly demonstrate that NF-κB activation and IκBα degradation are early events activated by doxorubicin and its analogues and that they play a critical pro-apoptotic role.
KW - Cytotoxicity
KW - Doxorubicin
KW - NBD peptide
KW - NF-κB
KW - RIP
KW - Transcription factor
UR - http://www.scopus.com/inward/record.url?scp=1642579534&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1642579534&partnerID=8YFLogxK
U2 - 10.1016/j.bcp.2003.08.039
DO - 10.1016/j.bcp.2003.08.039
M3 - Article
C2 - 14698047
AN - SCOPUS:1642579534
SN - 0006-2952
VL - 67
SP - 353
EP - 364
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
IS - 2
ER -